A parenteral nutrition regimen with ornithine substituted for arginine alters the amino acid, but not polyamine, content of the ward colon tumor.
Substituting ornithine for arginine in total parenteral nutrition (TPN) regimens eliminates the TPN-enhanced growth of the Ward colon tumor. Plasma arginine was increased when tumor growth was increased, suggesting a role for this amino acid. The erythrocyte polyamine content, however, was elevated in rats receiving both TPN regimens, indicating an increased synthesis and availability for tumors receiving arginine- and ornithine-containing regimens. The objective of this study, therefore, was to evaluate the effect of substituting ornithine for arginine in a TPN regimen on the amino acid and polyamine content of the Ward colon tumor compared with that of rats fed chow ad libitum. Male Fischer 344 rats with a transplantable Ward colon tumor implanted subcutaneously were randomized to three groups and fed for four days. One group received a TPN regimen with arginine (1,300 mg/100 ml, ENA), whereas a second group received a regimen with an isonitrogenous substitution of ornithine (ENO). A control group received chow ad libitum. Serum and tumors were evaluated for arginine, ornithine, lysine, and polyamine content. The arginine concentration in the serum and tumor increased when rats received ENA. In contrast, the serum and tumor arginine content for rats receiving ENO was significantly lower than that for rats receiving chow or ENA. Tumor and serum ornithine content was increased severalfold when ornithine was included in the regimen. Tumor polyamine content was not affected by TPN. The results show that serum and tumor arginine content are significantly altered by substituting ornithine for arginine in a TPN regimen. These and previous results suggest that TPN-enhanced growth of the Ward colon tumor when arginine is included in the formulation occurs by a mechanism other than increased polyamine synthesis.
Grossie
V B
VB
Department of Integrative Biology, University of Texas-Houston Medical School 77030, USA.
Nishioka
K
K
D000596:Amino Acids / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D000818:Animals; D001120:Arginine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D003110:Colonic Neoplasms / Q000097:blood / Q000737:chemistry* / Q000628:therapy; D008239:Lysine / Q000097:blood; D008297:Male; D009952:Ornithine / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010288:Parenteral Nutrition / Q000592:standards*; D011073:Polyamines / Q000032:analysis* / Q000097:blood / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
D000596:Amino Acids; D011073:Polyamines; D001120:Arginine; D009952:Ornithine; D008239:Lysine